论文信息 - Antidrug Antibodies in Patients Treated with Alirocumab. - 字舞流文

Antidrug Antibodies in Patients Treated with Alirocumab.

In 10 clinical trials involving 4747 patients, among those who received the PCSK9 inhibitor alirocumab, antidrug antibodies developed in 5.1%, although no significant effect was seen on the reduction in LDL cholesterol levels.

Albert Torri | A. Goldberg | G. Yancopoulos | N. Stahl | H. Colhoun | A. Catapano | George D Yancopoulos | Neil Stahl | Eli M Roth | Alberico L Catapano | Helen M Colhoun | Anne C Goldberg | Aurélie Brunet | Guillaume Lecorps | A. Torri | G. Lecorps | E. Roth | A. Brunet

[1] Jennifer G. Robinson,et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. , 2014, International journal of cardiology.

[2] Jennifer G. Robinson,et al. Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. , 2015, The Journal of clinical endocrinology and metabolism.

[3] M. Krempf,et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia , 2015, European heart journal.

[4] P. Ridker,et al. Lipid‐Reduction Variability and Antidrug‐Antibody Formation with Bococizumab , 2017, The New England journal of medicine.